Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa.
OBJECTIVES
The steady progress in resistance of Pseudomonas aeruginosa (PA) has led to difficulties in treating infections due to multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains. Ceftazidime/avibactam (CAZ/AVI) has in vitro activity against many of these strains, however clinical experience with CAZ/AVI is limited. This study aimed to evaluate the characteristics and outcomes of eight patients with infections due to MDR- or XDR-PA treated with CAZ/AVI, including four strains resistant to ceftolozane/tazobactam.


METHODS
This was a retrospective descriptive study of patients admitted to a teaching hospital between January 2016 and May 2017 who received CAZ/AVI as initial or continuation therapy for infection due to MDR- and XDR-PA.


RESULTS
The sources of infection were hospital-acquired lower respiratory tract infection in five patients (62.5%) and osteomyelitis, meningitis and catheter-related bacteraemia in one patient each. Clinical cure was achieved in 4 patients (50.0%). The 30-day and 90-day mortality rates were 12.5% and 37.5%, respectively. One patient (12.5%) developed encephalopathy that improved with discontinuation of the drug.


CONCLUSIONS
CAZ/AVI may be a valuable option for serious infections due to resistant PA.
['Rodríguez-Núñez|Olga|O|', 'Ripa|Marco|M|', 'Morata|Laura|L|', 'de la Calle|Cristina|C|', 'Cardozo|Celia|C|', 'Fehér|Csaba|C|', 'Pellicé|Martina|M|', 'Valcárcel|Andrea|A|', 'Puerta-Alcalde|Pedro|P|', 'Marco|Francesc|F|', 'García-Vidal|Carolina|C|', 'Del Río|Ana|A|', 'Soriano|Alex|A|', 'Martínez-Martínez|Jose Antonio|JA|']
D000368:Aged D000900:Anti-Bacterial Agents D053961:Azabicyclo Compounds D002442:Ceftazidime D024901:Drug Resistance, Multiple, Bacterial D005260:Female D006801:Humans D008297:Male D008826:Microbial Sensitivity Tests D008875:Middle Aged D011552:Pseudomonas Infections D011550:Pseudomonas aeruginosa D012189:Retrospective Studies D062606:Tertiary Care Centers D016896:Treatment Outcome
Ceftazidime/avibactam Multidrug-resistant Extensively drug-resistant Pseudomonas aeruginosa